# Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

> **NCT00478426** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Endometrial Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage IVA Uterine Corpus Cancer AJCC v7
- Stage IVB Uterine Corpus Cancer AJCC v7
- Uterine Carcinosarcoma
- Uterine Corpus Carcinosarcoma

## Interventions

- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00478426
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-30
- **Primary completion:** 2019-02-12
- **Final completion:** 2019-02-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478426, "Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00478426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*